Feb 23 (Reuters) - Ocugen Inc :
* EUROPEAN COMMISSION GRANTS OCUGEN ORPHAN MEDICINAL PRODUCT DESIGNATION FOR GENE THERAPY PRODUCT CANDIDATE, OCU400, FOR THE TREATMENT OF BOTH RETINITIS PIGMENTOSA AND LEBER CONGENITAL AMAUROSIS
Source text for Eikon: Further company coverage:
((Reuters.Briefs@thomsonreuters.com;))
精彩评论